BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

ARDX upcoming catalysts

Ardelyx: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 0 FDA event(s). Subscribe to ARDX (.ics).

Drugs: Tenapanor

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-08-20P3Ardelyx ARDXNCT05643534 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsIrritable Bowel Syndrome With Constipation (IBS-C)completed180
2026-07-07P2Ardelyx ARDXNCT06553547 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsIrritable Bowel Syndrome With Constipation (IBS-C)completed72

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.